
    
      Isotretinoin was administered to participants in the Isotretinoin arm at approximately 0.5
      mg/kg PO once daily for 4 weeks, then increased to approximately 1.0 mg/kg PO once daily for
      12 weeks. Follow-up continues to week 28 to evaluate the duration of effect. Randomization
      was stratified by willingness to participate in the gut biopsy substudy, A5330s. The study
      population included HIV-1 infected adults whose virus was suppressed on ART, excluding women
      of child bearing potential.
    
  